# US 11,906,520 B2 · Composition and methods for detecting cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,906,520 B2
- Document ID: US11906520B2
- Status: Granted
- Kind: B2
- Application number: 16/692,574
- Filed: 2019-11-22
- Published: 2020-05-28
- Granted: 2024-02-20
- Earliest claimed: 2018-11-23
- Assignees: Centre National De La Recherche Scientifique; Institut National De La Sante Et De La Rech. Med.; Universite Paris Est Creteil Val De Marne
- Applicants: Centre National De La Recherche Scientifique; Institut National De La Sante Et De La Recherche Medicale; Universite Paris Est Creteil Val De Marne
- Inventors: Valérie Molinier Frenkel; Flavia Castellano
- Web page: https://patentgrep.com/patent/US11906520B2

## CPC

- C07K 16/40: against enzymes
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- C07K 16/247: {IL-4}
- G01N 33/57585: {involving compounds identifiable in body fluids}
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to antibodies, which bind a peptide having a sequence selected from SEQ ID NO: 2, or a fragment or derivative of such an antibody having essentially the same antigen specificity. In particular, the antibodies suited to be used to detect, manage or monitor cancer in a subject, particularly cancer with interleukin-4 induced gene 1 (IL4I1) expressing cells. The invention also relates to kits or devices containing said antibodies, suitable for immunologic detection or reaction from any biological sample.

## Claims

### Claim 1

An isolated monoclonal antibody comprising:
a heavy chain comprising variable domain CDR sequences comprising:
(a) a H-CDR1 comprising the sequence of SEQ ID NO: 8,
(b) a H-CDR2 comprising the sequence of SEQ ID NO: 9 or SEQ ID NO: 18, and
(c) a H-CDR3 comprising the sequence of SEQ ID NO: 10 or SEQ ID NO: 19; and
a light chain comprising variable domain CDR sequences comprising:
(a) a L-CDR1 comprising the sequence of SEQ ID NO: 5,
(b) a L-CDR2 comprising the sequence of SEQ ID NO: 6 or SEQ ID NO: 14, and
(c) a L-CDR3 comprising the sequence of SEQ ID NO: 7 or SEQ ID NO: 15.

### Claim 2 (depends on 1)

The isolated monoclonal antibody according to claim 1, wherein:
the variable domain CDR sequences of the light chain consist of SEQ ID NO: 5 for L-CDR1, SEQ ID NO: 6 for L-CDR2 and SEQ ID NO: 7 for L-CDR3; and
the variable domain CDR sequences of the heavy chain consist of SEQ ID NO: 8 for H-CDR1, SEQ ID NO: 9 for H-CDR2 and SEQ ID NO: 10 for H-CDR3.

### Claim 3 (depends on 1)

The isolated monoclonal antibody according to claim 1, wherein:
the variable domain CDR sequences of the light chain consist of SEQ ID NO: 5 for L-CDR1, SEQ ID NO: 14 for L-CDR2 and SEQ ID NO: 15 for L-CDR3; and
the variable domain CDR sequences of the heavy chain consist of SEQ ID NO: 8 for H-CDR1, SEQ ID NO: 18 for H-CDR2 and SEQ ID NO: 19 for H-CDR3.

### Claim 4 (depends on 1)

A device comprising the isolated monoclonal antibody according to claim 1 immobilized on a support.

### Claim 5 (depends on 4)

The device of claim 4, wherein the support is a membrane, a slide, a microarray, a chip, a microbead or a quartz prism.

### Claim 6 (depends on 1)

A kit comprising the isolated monoclonal antibody according to claim 1.

### Claim 7 (depends on 6)

The kit according to claim 6 further comprising at least one reagent for performing or detecting an immune reaction.

### Claim 8

An isolated monoclonal antibody produced from the hybridoma cell available under CNCM deposit number I-5355.